Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Deals

Hotgen Biotech Partners with Genoval Therapeutics for RNAi Drug Development

Fineline Cube Oct 23, 2023

China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging...

Company Deals

Hansoh Pharmaceutical and GSK Ink Global Licensing Deal for Innovative ADC HS-20089

Fineline Cube Oct 23, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with...

Company Drug

InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023

Fineline Cube Oct 23, 2023

China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule...

Company Deals

Foundation Medicine Expands Genomic Profiling Partnership with Sequanta Technologies in China

Fineline Cube Oct 23, 2023

US-based Contract Research Organization (CRO) Foundation Medicine Inc. has announced the expansion of its existing...

Company Medical Device

Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific

Fineline Cube Oct 20, 2023

Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease...

Company Deals

Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million

Fineline Cube Oct 20, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9...

Company Drug

Beijing SL Pharmaceutical Gains NMPA Approval for Phase I Trial of MBT-1608 for Hepatitis C

Fineline Cube Oct 20, 2023

China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval...

Company Drug

Skyline Therapeutics Gains NMPA Approval for SKG0106 in Neovascular AMD Treatment

Fineline Cube Oct 20, 2023

Skyline Therapeutics has announced that it has received clinical trial approval from the National Medical...

Company Drug

Accuredit Therapeutics Initiates First Dosing of Gene Therapy ART001 for ATTR

Fineline Cube Oct 20, 2023

China-based gene therapy start-up Accuredit Therapeutics (Suzhou) Co., Ltd has announced the first dosing of...

Company

Bayer HealthCare Launches First Innovation Center in Beijing’s ETown

Fineline Cube Oct 20, 2023

Bayer HealthCare (ETR: BAYN) has formally inaugurated its inaugural innovation center in China, strategically situated...

Legal / IP Policy / Regulatory

China’s State Council Unveils Plan to Boost Patent Commercialization by 2025

Fineline Cube Oct 20, 2023

China’s State Council has recently approved the “Special Action Plan for Patent Commercialization and Utilization...

Company Drug

BMS’s Sotyktu Receives NMPA Approval for Psoriasis Treatment

Fineline Cube Oct 20, 2023

The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers...

Company Drug

CDE Grants Priority Review to Pearl Biotech’s Breatinib for Glioblastoma Treatment

Fineline Cube Oct 20, 2023

China’s Center for Drug Evaluation (CDE) has indicated that Beijing Pearl Biotechnology Co., Ltd’s breatinib...

Company

Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand

Fineline Cube Oct 20, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced...

Company Drug

BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC

Fineline Cube Oct 20, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...

Company Deals

Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases

Fineline Cube Oct 20, 2023

Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...

Company Deals

MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates

Fineline Cube Oct 20, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...

Company

HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy

Fineline Cube Oct 19, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease...

Company

Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion

Fineline Cube Oct 19, 2023

Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of...

Company Deals

Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics

Fineline Cube Oct 19, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with...

Posts pagination

1 … 491 492 493 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.